212 related articles for article (PubMed ID: 18596389)
21. Tamoxifen in the treatment of metastatic malignant melanoma: still a controversy? (Review).
Toma S; Ugolini D; Palumbo R
Int J Oncol; 1999 Aug; 15(2):321-37. PubMed ID: 10402244
[TBL] [Abstract][Full Text] [Related]
22. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
Wang Z; Zhou J; Fan J; Qiu SJ; Yu Y; Huang XW; Tang ZY
Clin Cancer Res; 2008 Aug; 14(16):5124-30. PubMed ID: 18698030
[TBL] [Abstract][Full Text] [Related]
23. Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib.
Jilaveanu L; Zito C; Lee SJ; Nathanson KL; Camp RL; Rimm DL; Flaherty KT; Kluger HM
Clin Cancer Res; 2009 Feb; 15(3):1076-85. PubMed ID: 19188183
[TBL] [Abstract][Full Text] [Related]
24. Sorafenib: tolerance in patients on chronic hemodialysis: a single-center experience.
Rey PM; Villavicencio H
Oncology; 2008; 74(3-4):245-6. PubMed ID: 18716419
[TBL] [Abstract][Full Text] [Related]
25. Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer.
Bianchi G; Loibl S; Zamagni C; Salvagni S; Raab G; Siena S; Laferriere N; Peña C; Lathia C; Bergamini L; Gianni L
Anticancer Drugs; 2009 Aug; 20(7):616-24. PubMed ID: 19739318
[TBL] [Abstract][Full Text] [Related]
26. Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer.
Bukowski R; Cella D; Gondek K; Escudier B;
Am J Clin Oncol; 2007 Jun; 30(3):220-7. PubMed ID: 17551296
[TBL] [Abstract][Full Text] [Related]
27. Sorafenib induces therapeutic response in a patient with metastatic collecting duct carcinoma of kidney.
Ansari J; Fatima A; Chaudhri S; Bhatt RI; Wallace M; James ND
Onkologie; 2009 Feb; 32(1-2):44-6. PubMed ID: 19209019
[TBL] [Abstract][Full Text] [Related]
28. Cutaneous melanoma: available therapy for metastatic disease.
Tarhini AA; Agarwala SS
Dermatol Ther; 2006; 19(1):19-25. PubMed ID: 16405566
[TBL] [Abstract][Full Text] [Related]
29. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
[TBL] [Abstract][Full Text] [Related]
30. Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial.
Richly H; Schultheis B; Adamietz IA; Kupsch P; Grubert M; Hilger RA; Ludwig M; Brendel E; Christensen O; Strumberg D
Eur J Cancer; 2009 Mar; 45(4):579-87. PubMed ID: 19101137
[TBL] [Abstract][Full Text] [Related]
31. Sorafenib-induced erythema multiforme in metastatic renal cell carcinoma.
Bilaç C; Müezzinoğlu T; Ermertcan AT; Kayhan TC; Temeltaş G; Oztürkcan S; Temiz P
Cutan Ocul Toxicol; 2009; 28(2):90-2. PubMed ID: 19514932
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapy and targeted therapy combinations in advanced melanoma.
Flaherty KT
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2366s-2370s. PubMed ID: 16609060
[TBL] [Abstract][Full Text] [Related]
33. Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial.
Rimassa L; Santoro A
Expert Rev Anticancer Ther; 2009 Jun; 9(6):739-45. PubMed ID: 19496710
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
[TBL] [Abstract][Full Text] [Related]
35. Sorafenib for the treatment of unresectable hepatocellular carcinoma.
Kane RC; Farrell AT; Madabushi R; Booth B; Chattopadhyay S; Sridhara R; Justice R; Pazdur R
Oncologist; 2009 Jan; 14(1):95-100. PubMed ID: 19144678
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
Rini BI; Wilding G; Hudes G; Stadler WM; Kim S; Tarazi J; Rosbrook B; Trask PC; Wood L; Dutcher JP
J Clin Oncol; 2009 Sep; 27(27):4462-8. PubMed ID: 19652060
[TBL] [Abstract][Full Text] [Related]
37. Sorafenib: a clinical and pharmacologic review.
Iyer R; Fetterly G; Lugade A; Thanavala Y
Expert Opin Pharmacother; 2010 Aug; 11(11):1943-55. PubMed ID: 20586710
[TBL] [Abstract][Full Text] [Related]
38. A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma.
Markovic SN; Suman VJ; Rao RA; Ingle JN; Kaur JS; Erickson LA; Pitot HC; Croghan GA; McWilliams RR; Merchan J; Kottschade LA; Nevala WK; Uhl CB; Allred J; Creagan ET
Am J Clin Oncol; 2007 Jun; 30(3):303-9. PubMed ID: 17551310
[TBL] [Abstract][Full Text] [Related]
39. Antitumor efficacy of recombinant human interleukin-2 combined with sorafenib against mouse renal cell carcinoma.
Iguchi M; Matsumoto M; Hojo K; Wada T; Matsuo Y; Arimura A; Abe K
Jpn J Clin Oncol; 2009 May; 39(5):303-9. PubMed ID: 19336449
[TBL] [Abstract][Full Text] [Related]
40. Cutaneous drug eruptions induced by sorafenib: a case series.
Maddox JS; Kung EF; Petronic-Rosic V; Sethi A
J Drugs Dermatol; 2008 Sep; 7(9):891-3. PubMed ID: 19112807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
